How does interferon work? Does it even matter?

This publication has 14 references indexed in Scilit:

• Immunomodulatory effects of high‐dose and low‐dose interferon α2b in patients with high‐risk resected melanoma
  Cancer, 2002
• Interferon Alfa Therapy for Malignant Melanoma: A Systematic Review of Randomized Controlled Trials
  Journal of Clinical Oncology, 2002
• Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study
  British Journal of Cancer, 2001
• Sentinel Lymph Node Biopsy for Melanoma: How Many Radioactive Nodes Should be Removed?
  Annals of Surgical Oncology, 2001
• Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases
  The Lancet, 1998
• Postsurgical adjuvant therapy for melanoma
  Cancer, 1997
• Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
  Journal of Clinical Oncology, 1996
• Randomized Trial of Adjuvant Human Interferon Gamma Versus Observation in High-Risk Cutaneous Melanoma: a Southwest Oncology Group Study
  JNCI Journal of the National Cancer Institute, 1995
• Results of adjuvant interferon study In WHO melanoma programme
  The Lancet, 1994
• Rationale for Recombinant Human Interferon-Gamma Adjuvant Immunotherapy for Cancer
  JNCI Journal of the National Cancer Institute, 1988